Targeted PET imaging could revolutionize cancer treatment selection
NCT ID NCT07554742
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new PET imaging tracer, [68Ga]Ga-NODAGA-SNA014, to detect a protein called Claudin18.2 in pancreatic and stomach cancers. The goal is to see if the scan can accurately identify patients whose tumors have this protein, which could help doctors choose the right targeted therapy. The trial will involve 64 participants with confirmed cancer and will compare scan results with tissue samples.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
[68Ga]Ga-NODAGA-SNA014 (a radioactive tracer for PET imaging)
What this could lead to
If successful, this imaging method could help doctors identify which patients are most likely to benefit from Claudin18.2-targeted therapies, enabling more personalized cancer treatment.
What could go wrong
This is an early-stage imaging study with only 64 participants, so results may not apply to all patients. The tracer's accuracy and safety are still being evaluated.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ruijin Hospital affiliated to Shanghai Jiao Tong University of Medicine
Shanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••